Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 427,009
  • Shares Outstanding, K 54,815
  • Annual Sales, $ 95,390 K
  • Annual Income, $ -368,010 K
  • 60-Month Beta 1.76
  • Price/Sales 4.06
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.58
  • Number of Estimates 5
  • High Estimate -1.32
  • Low Estimate -1.83
  • Prior Year -1.88
  • Growth Rate Est. (year over year) +15.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.93 +155.63%
on 10/28/19
8.20 -8.66%
on 11/19/19
+4.15 (+124.25%)
since 10/18/19
3-Month
2.93 +155.63%
on 10/28/19
8.20 -8.66%
on 11/19/19
+1.46 (+24.21%)
since 08/20/19
52-Week
2.93 +155.63%
on 10/28/19
32.05 -76.63%
on 02/28/19
-9.88 (-56.88%)
since 11/20/18

Most Recent Stories

More News
Shares of Clovis Oncology Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (CLVS , PBYI , ARWR, ALNY , CYTK )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CLVS : 7.33 (-5.91%)
PBYI : 8.50 (+1.19%)
ARWR : 48.11 (-4.73%)
Clovis Oncology Rises 10.27% on Heavy Volume: Watch For Potential Pullback

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $7.38 to a high of $8.20. Yesterday, the shares gained 10.3%, which took the trading range above the 3-day high of...

CLVS : 7.33 (-5.91%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Clovis Oncology (CLVS , ESPR , NBIX , RGEN , AGIO )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CLVS : 7.33 (-5.91%)
ESPR : 44.33 (-2.89%)
NBIX : 113.30 (+0.51%)
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

PTH : 86.93 (+0.27%)
PBE : 53.23 (+0.59%)
XBI : 87.26 (+0.06%)
CNCR : 22.22 (+1.19%)
DXCM : 221.61 (+1.85%)
CLVS : 7.33 (-5.91%)
BIIB : 285.98 (+0.19%)
PTI : 1.24 (+13.76%)
AQST : 5.80 (+6.62%)
FTSV : 11.71 (+6.75%)
ARKG : 33.04 (+0.64%)
Relatively Good Performance Detected in Shares of Clovis Oncology in the Biotechnology Industry (CLVS , EXEL , ARWR, TGTX , CHRS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

CLVS : 7.33 (-5.91%)
EXEL : 16.36 (-1.03%)
ARWR : 48.11 (-4.73%)
Clovis Oncology Announces Reimbursement for Rubraca(R) (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for monotherapy...

CLVS : 7.33 (-5.91%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Clovis Oncology (CLVS , ACAD , HRTX , ARWR, SRPT )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ACAD : 46.19 (-1.32%)
CLVS : 7.33 (-5.91%)
HRTX : 23.44 (+1.08%)
ARWR : 48.11 (-4.73%)
Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

CLVS : 7.33 (-5.91%)
Look for Shares of Clovis Oncology to Potentially Pullback after Yesterday's 60.58% Rise

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $4.29 to a high of $5.09. Yesterday, the shares gained 60.6%, which took the trading range above the 3-day high of...

CLVS : 7.33 (-5.91%)
Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up

Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.

BMY : 55.98 (-0.89%)
IMMU : 18.82 (+0.43%)
CLVS : 7.33 (-5.91%)
ALKS : 20.07 (+0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 8.74
1st Resistance Point 8.27
Last Price 7.29
1st Support Level 7.25
2nd Support Level 6.70

See More

52-Week High 32.05
Fibonacci 61.8% 20.93
Fibonacci 50% 17.49
Fibonacci 38.2% 14.05
Last Price 7.29
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar